Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies

Understanding the pharmacokinetic (PK) properties of a drug, such as clearance, is a crucial step for evaluating efficacy. The PK of therapeutic antibodies can be complex and is influenced by interactions with the target, Fc-receptors, anti-drug antibodies, and antibody intrinsic factors. A growing...

Descripción completa

Detalles Bibliográficos
Autores principales: Grinshpun, Boris, Thorsteinson, Nels, Pereira, Joao NS, Rippmann, Friedrich, Nannemann, David, Sood, Vanita D., Fomekong Nanfack, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204999/
https://www.ncbi.nlm.nih.gov/pubmed/34116620
http://dx.doi.org/10.1080/19420862.2021.1932230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204999/
https://www.ncbi.nlm.nih.gov/pubmed/34116620
http://dx.doi.org/10.1080/19420862.2021.1932230

Ejemplares similares